PHILADELPHIA, PA — May 23, 2002 —
Switching schizophrenic patients to new antipsychotic aripiprazole from both conventional and atypical antipsychotics appears to be both safe and well tolerated. For the study, 311 stable schizophrenic patients taking olanzapine, risperidone, or haloperidol were switched to aripiprazole using one of three switching strategies.
These strategies consisted of a switch to a full dose of aripiprazole without titration from prior antipsychotic treatment, switching to a full dose of aripiprazole along with tapering of the previous treatment for two weeks, or switching to aripiprazole with titration up along with titration down of the previous medication over two weeks.
The study was led by Daniel E. Casey, MD, from the Mental Illness Research, Education, and Clinical Center of the Portland Veterans Administration Medical Center in Oregon, United States.
The study was presented here this week at the annual meeting of the American Psychiatric Association (APA). Regardless of the switching strategy employed, the switching process was generally safe and well tolerated. Eight weeks after switching to aripiprazole, patients showed improvements in extrapyramidal symptoms (EPS) and reductions in prolactin levels and weight. They also showed statistically significant improvements in the Positive and Negative Syndrome Scale (PANSS).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!